Showing 21-30 of 3165 results for "".
Moving Toward a More Tolerable Treatment for AK
https://practicaldermatology.com/topics/general-topics/moving-toward-a-more-tolerable-treatment-for-ak/20760/A conversation with Peter Friedman, MD, PhD about non-thermal, atmospheric pressure plasma.Acne & Rosacea: 2020 and Beyond
https://practicaldermatology.com/topics/acne-rosacea/acne-rosacea-2020-and-beyond/19734/Guy Webster, MD, PhD reviews developments in acne and rosacea.SCALE 2024: Dr. Joel Cohen Interviews Dr. Saranya Wyles on Exosomes
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-joel-cohen-interviews-dr-saranya-wyles-exosomes/26364/Saranya Wyles, MD, PhD, joins Joel Cohen, MD, to discuss her research on exosomes at Music City SCALE.Take 5 With Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman of Tarsus Pharmaceuticals
https://practicaldermatology.com/columns/take-5/take-5-with-bobak-azamian-md-phd-chief-executive-officer-and-chairman-of-tarsus-pharmaceuticals/23982/Close Up With Martina M. Cartwright, PhD
https://practicaldermatology.com/topics/skin-of-color/close-up-with-martina-m-cartwright-phd/23985/Addressing the Unique Challenges of AD Patients
https://practicaldermatology.com/series/c-suite-chats/addressing-the-unique-challenges-of-ad-patients/28617/Patrick Burnett, MD, PhD, Chief Medical Officer at Arcutis Bioteheraputics, discusses the promise of the company’s roflumilast cream for AD.Dysregulation of Type 2 Immune Pathway
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/dysregulation-of-type-2-immune-pathway/48788/Raj Chovatiya, MD, PhD, MSCI, FAAD, discusses the role of type 2 inflammatory response in immune dysregulation in atopic dermatitis.IL-31’s Role in Prurigo Nodularis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/il-31s-role-in-prurigo-nodularis/48804/Raj Chovatiya, MD, PhD, MSCI, FAAD, explains the role of the IL-31 pathway in neuroinflammatory disease such as prurigo nodularis.Navigating the Latest Therapeutic Options
https://practicaldermatology.com/issues/october-2025/navigating-the-latest-therapeutic-options/39762/A Q&A With Raj Chovatiya, MD, PhD, MSCI, FAADPD Asks: What would your staff say is the one thing you do that most aggravates them?
https://practicaldermatology.com/topics/practice-management/pd-asks-what-would-your-staff-say-is-the-one-thing-you-do-that-most-aggravates-them/19695/John E. Harris, MD, PhD explains why his frequent travel might leave his staff feeling a bit annoyed at times!